These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 8825266)

  • 1. Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients.
    Dupont E; Andersen A; Boas J; Boisen E; Borgmann R; Helgetveit AC; Kjaer MO; Kristensen TN; Mikkelsen B; Pakkenberg H; Presthus J; Stien R; Worm-Petersen J; Buch D
    Acta Neurol Scand; 1996 Jan; 93(1):14-20. PubMed ID: 8825266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of early Parkinson's disease with controlled-release levodopa preparations.
    Rinne UK; Rinne JO
    Neurology; 1989 Nov; 39(11 Suppl 2):78-81; discussion 95. PubMed ID: 2586766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A controlled release form of madopar in parkinsonian patients with advanced disease and marked fluctuations in motor performance.
    Jensen NO; Dupont E; Hansen E; Mikkelsen B; Mikkelsen BO
    Acta Neurol Scand; 1988 May; 77(5):422-5. PubMed ID: 3046226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.
    Grahnén A; Eckernäs SA; Collin C; Ling-Andersson A; Tiger G; Nilsson M
    Eur Neurol; 1992; 32(6):343-8. PubMed ID: 1490503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of standard Madopar and controlled release Madopar in Parkinson's disease.
    Graham JS; Henderson JM; Morris JG; Yiannikas C
    Aust N Z J Med; 1991 Feb; 21(1):11-5. PubMed ID: 2036070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative single- and multiple-dose pharmacokinetics of levodopa and 3-O-methyldopa following a new dual-release and a conventional slow-release formulation of levodopa and benserazide in healthy volunteers.
    Crevoisier C; Monreal A; Metzger B; Nilsen T
    Eur Neurol; 2003; 49(1):39-44. PubMed ID: 12464717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the effects of controlled-release levodopa (Madopar CR) with conventional levodopa in late Parkinson's disease.
    MacMahon DG; Sachdev D; Boddie HG; Ellis CJ; Kendal BR; Blackburn NA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):220-3. PubMed ID: 2182781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Open multicenter trial with Madopar HBS in parkinsonian patients. Preliminary assessment after short-term treatment.
    Jansen EN; Meerwaldt JD; Heersema T; van Manen J; Speelman JD
    Eur Neurol; 1987; 27 Suppl 1():88-92. PubMed ID: 3322841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose studies of a slow-release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease.
    Marion MH; Stocchi F; Malcolm SL; Quinn NP; Jenner P; Marsden CD
    Eur Neurol; 1987; 27 Suppl 1():54-8. PubMed ID: 3322837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Madopar HBS (hydrodynamically balanced system) in the treatment of Parkinson's disease.
    Lees AJ
    Adv Neurol; 1990; 53():475-82. PubMed ID: 2239487
    [No Abstract]   [Full Text] [Related]  

  • 13. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and tolerability of a new levodopa/benserazide dual-release formulation in parkinsonian patients. L-Dopa Dual-Release Study Group.
    Ghika J; Gachoud JP; Gasser U
    Clin Neuropharmacol; 1997 Apr; 20(2):130-9. PubMed ID: 9099465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of Madopar CR and standard Madopar in the treatment of nocturnal and early-morning disability in Parkinson's disease. The U.K. Madopar CR Study Group.
    Clin Neuropharmacol; 1989 Dec; 12(6):498-505. PubMed ID: 2691069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Madopar HBS in Parkinson patients with nocturnal akinesia.
    Jansen EN; Meerwaldt JD
    Clin Neurol Neurosurg; 1988; 90(1):35-9. PubMed ID: 3359732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Madopar HBS in the long-term treatment of parkinsonian patients with fluctuations in disability.
    Rinne UK
    Eur Neurol; 1987; 27 Suppl 1():120-5. PubMed ID: 3428305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Open study of sustained-release formulation of levodopa and benserazide in parkinsonian patients.
    Kostić VS; Covicković-Sternić N
    Neurologija; 1990; 39(2):99-105. PubMed ID: 2267052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.
    Block G; Liss C; Reines S; Irr J; Nibbelink D
    Eur Neurol; 1997; 37(1):23-7. PubMed ID: 9018028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Madopar HBS in fluctuating parkinsonian patients: two-year treatment.
    Pezzoli G; Tesei S; Ferrante C; Cossutta E; Zecchinelli A; Scarlato G
    Mov Disord; 1988; 3(1):37-45. PubMed ID: 3050471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.